

**Retraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng, Y. Yuan. *Aliment Pharmacol Ther.* 2015;42:845–854.**

The above article from *Alimentary Pharmacology & Therapeutics*, published online on 31 July 2015 on Wiley Online Library (wileyonlinelibrary.com), and in Volume 42, pp. 845-854, has been retracted by agreement between the authors, J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng and Y. Yuan, the journal Editors in Chief, J. M. Rhodes and C. W. Howden, and John Wiley Sons Ltd. The retraction has been agreed upon following major protocol deviations at some study sites and several instances of non-compliance that are sufficiently serious to warrant the withdrawal of the Chinese New Drug Application for Gaviscon Double Action.